Ultragenyx Pharmaceutical Inc.

RARE Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
RARE Income Statement
RARE Balance Sheet
RARE Cash Flow
Congress Trading

Recent trades of RARE by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
RARE Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
RARE Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
RARE Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by RARE's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $80,000 Oct 21, 2024 Issue: Medicare/Medicaid Budget/Appropriations Health Issues
  • $30,000 Jul 22, 2024 Issue: Medicare/Medicaid Budget/Appropriations Health Issues
  • $220,000 Apr 22, 2024 Issue: Medicare/Medicaid Budget/Appropriations Health Issues
  • $40,000 Jan 11, 2024 Issue: Health Issues
  • $40,000 Oct 17, 2023 Issue: Health Issues
  • $60,000 Jul 16, 2023 Issue: Health Issues
  • $50,000 May 03, 2023 Issue: Health Issues
  • $50,000 Oct 17, 2022 Issue: Health Issues
  • $50,000 Jul 17, 2022 Issue: Health Issues
  • $50,000 Apr 17, 2022 Issue: Health Issues
  • $50,000 Jan 20, 2022 Issue: Pharmacy Health Issues
  • $50,000 Jan 18, 2022 Issue: Health Issues
  • $50,000 Oct 20, 2021 Issue: Health Issues Pharmacy
  • $50,000 Oct 19, 2021 Issue: Health Issues
  • $45,000 Jul 20, 2021 Issue: Health Issues
  • $20,000 Jul 19, 2021 Issue: Health Issues
  • $50,000 Jul 18, 2021 Issue: Health Issues
  • $50,000 Apr 20, 2021 Issue: Pharmacy Health Issues
  • $50,000 Apr 20, 2021 Issue: Health Issues
  • $10,000 Apr 19, 2021 Issue: Health Issues
  • $50,000 Jan 21, 2021 Issue: None
  • $40,000 Jan 20, 2021 Issue: Budget/Appropriations Health Issues
  • $20,000 Oct 20, 2020 Issue: Pharmacy Health Issues
  • $50,000 Oct 20, 2020 Issue: Budget/Appropriations Health Issues
  • $50,000 Jul 20, 2020 Issue: Pharmacy
  • $40,000 Jul 19, 2020 Issue: Health Issues
  • $10,000 Apr 20, 2020 Issue: Pharmacy
  • $40,000 Apr 20, 2020 Issue: Health Issues
  • $40,000 Jan 20, 2020 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Engineered producer cell lines and methods of making and using the same Jun. 25, 2024
  • Patent Title: Methods of heat inactivation of adenovirus Apr. 02, 2024
  • Patent Title: Cell culture methods involving hdac inhibitors or rep proteins Feb. 13, 2024
  • Patent Title: Use of tonicifying agents to enhance recombinant adeno-associated virus yield Oct. 24, 2023
  • Patent Title: Methods for treating tumor-induced osteomalacia Oct. 03, 2023
  • Patent Title: Creatine prodrugs, compositions and methods of use thereof Sep. 12, 2023
  • Patent Title: Therapeutics for glycogen storage disease type iii Jul. 05, 2022
  • Patent Title: Creatine prodrugs, compositions and methods of use thereof May. 17, 2022
  • Patent Title: Methods for treating hypophosphatemic disorders Dec. 21, 2021
  • Patent Title: Methods of heat inactivation of adenovirus May. 25, 2021
  • Patent Title: Sialic acid analogs Jan. 12, 2021
  • Patent Title: Methods for treating hypophosphatemic disorders May. 05, 2020
  • Patent Title: Sialic acid analogs Oct. 29, 2019
  • Patent Title: Crystal forms of sialic acid or salt or solvate thereof Aug. 20, 2019
  • Patent Title: Sialic acid analogs Sep. 04, 2018
  • Patent Title: Sialylated glycoprotein compositons and uses thereof Jun. 27, 2017
  • Patent Title: Methods and formulations for treating sialic acid deficiencies Jan. 31, 2017
  • Patent Title: Methods and formulations for treating sialic acid deficiencies Dec. 06, 2016
  • Patent Title: Sialylated glycoprotein compositions and uses thereof Oct. 04, 2016
  • Patent Title: Sialylated glycoprotein compositions and uses thereof Oct. 04, 2016
  • Patent Title: Methods and formulations for treating sialic acid deficiencies Jan. 26, 2016
  • Patent Title: Sialic acid analogs Dec. 29, 2015
  • Patent Title: Sialic acid analogs Sep. 23, 2014
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of RARE in WallStreetBets Daily Discussion

RARE News

Recent insights relating to RARE

CNBC Recommendations

Recent picks made for RARE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RARE

RARE Top Shareholders
Shareholder
Shares Held
RARE Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

RARE Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view RARE Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top